Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

vlucky16 Sep. 14 at 11:31 PM

$SLS BO = PARADISE

0 · Reply

waterboy182 Sep. 14 at 11:30 PM

$SLS Im not posting anything ridonculous. Crazy shit. Hard Knocks. We will be back in 2 days, lol Somebody stop this train! NOW, is the time time to buy you sideLine Griftors... no

0 · Reply

Mr_Anderson007 Sep. 14 at 11:28 PM

$SLS Looking to deploy upwards of 6 figures this week…a little dessert…but will only deploy if F-WADs make another move.

0 · Reply

MOOSEN Sep. 14 at 11:26 PM

$SLS THIS STOCK WILL—HEALTHILY—PROVIDE HEAPS OF GLEANING RE TRADING TA AND HOW CHAIN INDICATIONS, TECHNICALS, STRADDLES, BIG BOY MALVERSATIONS, ASSOCIATIVE TIMELINES, MARKET TRENDS, ET AL CAN ALL AFFECT NEEDLE BEHAVIOUR; GRID AIN’T TOO CHALLENGING EITHER, TO BOOT. I’VE TRULY APPRECIATED BEING APPLIED IN DEEPENING MY ROOTS AND RECALIBRATIONS AROUND MY CORE SINCE MY INCEPTION IN FEB 24. CONTINUE TO DEVELOP VIA HONING YOUR INTUITION. BEST OUT THERE, YOU FUCKING MONSTERS.

0 · Reply

vlucky16 Sep. 14 at 11:25 PM

$SLS Sterge call this in the morning. Last Friday was a practice run for this Friday and someone has to teach these guys a lesson they will not forget for the rest of their lives. Price target has gone through the roof for SLS, since GPS- Longevity, Curative, WT1 cancer platform. CDK9 inhibitor safe, 009 Pancreatic cancer (RVMD over 200 a share for 13.5 month survival) 009 survival will blow out RVMD and 20 other CDK9 cancers. Only thing to slow this down would be trick play by IDMC on behalf of BP to stall the inevitable.

1 · Reply

Biobanker Sep. 14 at 11:15 PM

$SLS Personally I find it easier to hold my shares and not check this page 😆. Go all the way, or none of the way. NFA

1 · Reply

foolforlove20 Sep. 14 at 11:11 PM

$SLS until data is released there will be shake outs. Happens to every bio waiting on a read out or FDA approval. Standard game rules; Bears will spin the drops as something significant with AI posts. Bulls will spin the bounces as something significant with AI posts. Fear and hype cycle, repeat. All you need to do is do your DD, hold your shares, ditch your stoploss and profit. Oh, and don't buy on margin if your account can't handle the swings. It's pretty easy actually..

0 · Reply

JdNews Sep. 14 at 11:11 PM

$SLS Forte biosciences. Bought out at 77$. We should go for 88. But, maybe that’s liw?

0 · Reply

Wealthy500 Sep. 14 at 11:04 PM

$SLS 11.71 or 60+ or 100+ or 160+ . Which way is it going to go? :-)

0 · Reply

missile_systems Sep. 14 at 11:00 PM

$SLS doing my part guys and gals… snagged a hunny more . 🙏🇺🇸😎 GO BIRDS ! 🦅 🦅 🦅

0 · Reply

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

2026-08-24T13:52:50.000Z - 21 days ago

SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon

2026-08-19T15:15:54.000Z - 26 days ago

Moderna data bode well for Sellas into imminent readout, says Maxim

MRNA

2026-08-17T09:58:27.000Z - 4 weeks ago

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Aug 11, 2026, 4:05 PM EDT - 4 weeks ago

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

SELLAS Life Sciences Group Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

SELLAS Life Sciences Group Earnings release: Q2 2026

2026-07-17T16:06:56.000Z - 1 month ago

Sellas Life Sciences rises 11.0%

2026-07-17T14:05:57.000Z - 1 month ago

Sellas Life Sciences rises 10.2%

2026-07-06T11:05:22.000Z - 2 months ago

Sellas Life Sciences price target raised to $25 from $10 at Alliance Global

2026-07-01T14:05:22.000Z - 2 months ago

Sellas Life Sciences falls -11.0%

2026-06-30T14:05:32.000Z - 2 months ago

Sellas Life Sciences falls -8.9%

2026-06-29T14:05:39.000Z - 2 months ago

Sellas Life Sciences rises 16.8%

Jun 26, 2026, 12:30 PM EDT - 2 months ago

What's driving SLS stock higher today and what comes next?

Jun 16, 2026, 8:30 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: AGM 2026

May 27, 2026, 9:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026, 11:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 14, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 4 months ago

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Mar 27, 2026, 8:05 AM EDT - 5 months ago

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

Mar 19, 2026, 4:05 PM EDT - 5 months ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 6 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 12, 2026, 8:35 AM EDT - 6 months ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Jan 14, 2026, 8:30 AM EST - 8 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 8 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 9 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

SELLAS Life Sciences Group Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

SELLAS Life Sciences Group Quarterly report: Q3 2025

Oct 29, 2025, 10:00 AM EDT - 10 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 10 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Oct 10, 2025, 8:00 AM EDT - 11 months ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 10, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Jun 5, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q1 2025

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Annual report: Q4 2024

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Press release: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Earnings release: Q3 2024

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 2 years ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q1 2024

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Press release: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

vlucky16 Sep. 14 at 11:31 PM

$SLS BO = PARADISE

0 · Reply

waterboy182 Sep. 14 at 11:30 PM

$SLS Im not posting anything ridonculous. Crazy shit. Hard Knocks. We will be back in 2 days, lol Somebody stop this train! NOW, is the time time to buy you sideLine Griftors... no

0 · Reply

Mr_Anderson007 Sep. 14 at 11:28 PM

$SLS Looking to deploy upwards of 6 figures this week…a little dessert…but will only deploy if F-WADs make another move.

0 · Reply

MOOSEN Sep. 14 at 11:26 PM

0 · Reply

vlucky16 Sep. 14 at 11:25 PM

1 · Reply

Biobanker Sep. 14 at 11:15 PM

$SLS Personally I find it easier to hold my shares and not check this page 😆. Go all the way, or none of the way. NFA

1 · Reply

foolforlove20 Sep. 14 at 11:11 PM

0 · Reply

JdNews Sep. 14 at 11:11 PM

$SLS Forte biosciences. Bought out at 77$. We should go for 88. But, maybe that’s liw?

0 · Reply

Wealthy500 Sep. 14 at 11:04 PM

$SLS 11.71 or 60+ or 100+ or 160+ . Which way is it going to go? :-)

0 · Reply

missile_systems Sep. 14 at 11:00 PM

$SLS doing my part guys and gals… snagged a hunny more . 🙏🇺🇸😎 GO BIRDS ! 🦅 🦅 🦅

0 · Reply

waterboy182 Sep. 14 at 10:55 PM

$SLS I have no explanation for this stupidity. Carry on. Buy more lower. If we hit the 80th in 2030,lol.

0 · Reply

brian4sw Sep. 14 at 10:49 PM

$SLS you can’t make this stuff up!

2 · Reply

Zyntax Sep. 14 at 10:48 PM

$SLS Who thinks we all become John Connors and fight Skynet in year 2030? 😂

1 · Reply

mjd32jax Sep. 14 at 10:46 PM

$SLS Weak hands sold.. let's fly high now!

0 · Reply

moneymaker444 Sep. 14 at 10:44 PM

$SLS Friday should be interesting. Opex quad witching 🧐we shall see

0 · Reply

bigbigwin Sep. 14 at 10:44 PM

$SLS 🫡👍🙌

0 · Reply

MisplacedOkie Sep. 14 at 10:33 PM

$SLS every time they shake the tree, it makes it just a little bit harder to shake the remaining retail holders

1 · Reply

dewmoore Sep. 14 at 10:30 PM

$VERA Yo! Who is on the CONFERENCE CALL -- should be good insights https://event.webcasts.com/viewer/event.jsp?ei=1773634&tp_key=bf68b41041 ohhh by the way the guy/girl who gave me $SLS is also on the call too they are dropping their Reddit post soon --I saw the first draft and WOW i can't wait to post the link when they are done but they wanna see what is said TONIGHT and then they will drop the post --- "$35 VERA To Hit $100+ in September & Crush $40B Kidney King """***I love the headline already lol I'm clicking allllll day because they made it soo simple and easy to understand !!!! ok we are waiting as they play classical music lol

0 · Reply

JdNews Sep. 14 at 10:27 PM

$SLS 8$ bavk in July. Ripped to 15.85. Back agsin for around 2.

1 · Reply

RealImbackbears Sep. 14 at 10:17 PM

$SLS This is what Bulls have to look forward too as a SLS investor, Kamala youtube.com/shorts/a2R2d5Yrmc4 Bu

3 · Reply

yft212 Sep. 14 at 10:17 PM

$SLS As a micro-cap biopharmaceutical company, FDA approval would transition SLS from a pre-revenue R&D outfit into a commercial-stage powerhouse. And don't forget the FDA granted GPS a Rare Pediatric Disease Designation (RPDD) for pediatric AML... approval triggers the issuance of a transferable Priority Review Voucher (PRV). These vouchers are highly coveted by major pharmaceutical companies to fast-track their own blockbusters and routinely sell on the open market for approximately $100 million. Glad I own shares and not options. I prefer to own a piece of my investment. Paid to fish not post!

3 · Reply

topstockalerts Sep. 14 at 10:16 PM

$SLS definitely worth keeping an eye on

0 · Reply

Market Cap	2.33B
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	10,505,400
Avg Vol	7,363,862
Day's Range	N/A - N/A
Shares Out	201.95M
Stochastic %K	5%
Beta	2.52
Analysts	Strong Sell
Price Target	$32.50